|
|
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of CKD-501 and D759 in Healthy Adults
The purpose of this study is to evaluate the pharmacokinetics and safety of CKD-396.
100 Clinical Results associated with DPP-4 x PPARγ x PPARα
100 Translational Medicine associated with DPP-4 x PPARγ x PPARα
0 Patents (Medical) associated with DPP-4 x PPARγ x PPARα